Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

被引:50
|
作者
Ritz, E. [1 ]
Viberti, G. C. [11 ]
Ruilope, L. M. [2 ]
Rabelink, A. J. [3 ]
Izzo, J. L., Jr. [4 ]
Katayama, S. [5 ]
Ito, S. [6 ]
Mimran, A. [7 ]
Menne, J. [10 ]
Rump, L. C. [8 ]
Januszewicz, A. [9 ]
Haller, H. [10 ]
机构
[1] Heidelberg Univ, Dept Nephrol, Heidelberg, Germany
[2] Hosp 12 Octubre, Div Hypertens, E-28041 Madrid, Spain
[3] Leiden Univ, Med Ctr, Dept Hypertens & Nephrol, Leiden, Netherlands
[4] Erie Cty Med Ctr & Labs, Dept Med, Buffalo, NY USA
[5] Saitama Med Sch, Dept Med 4, Iruma, Saitama, Japan
[6] Tohoku Univ, Grad Sch Med, Dept Clin Med, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi 980, Japan
[7] Hop Lapeyronie, Montpellier, France
[8] Ruhr Univ Bochum, Univ Clin, Med Clin, Marienhosp Herne, D-4690 Herne, Germany
[9] Inst Cardiol, Dept Hypertens, Warsaw, Poland
[10] Hannover Med Sch, Dept Hypertens & Nephrol, D-30625 Hannover, Germany
[11] KCL Guys Hosp, London, England
关键词
Albuminuria; Diabetes; Diabetic nephropathy; Epidemiology; Hypertension; Proteinuria; AMBULATORY BLOOD-PRESSURE; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR RISK; METABOLIC SYNDROME; FOLLOW-UP; NONDIABETIC SUBJECTS; WAIST CIRCUMFERENCE; INSULIN-RESISTANCE; NATURAL-HISTORY; PULSE PRESSURE;
D O I
10.1007/s00125-009-1577-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In contrast to microalbuminuric type 2 diabetic patients, the factors correlated with urinary albumin excretion are less well known in normoalbuminuric patients. This may be important because even within the normoalbuminuric range, higher rates of albuminuria are known to be associated with higher renal and cardiovascular risk. At the time of screening for the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Study, the urinary albumin/creatinine ratio (UACR) was 0.44 mg/mmol in 4,449 type 2 diabetic patients. The independent correlates of UACR were analysed. Independent correlates of UACR during baseline were (in descending order): night-time systolic BP (r (s) = 0.19); HbA(1c) (r (s) = 0.18); mean 24 h systolic BP (r (s) = 0.16); fasting blood glucose (r (s) = 0.16); night-time diastolic BP (r (s) = 0.12); office systolic BP, sitting (r (s) = 0.11), standing (r (s) = 0.10); estimated GFR (r (s) = 0.10); heart rate, sitting (r (s) = 0.10); haemoglobin (r (s) = -0.10); triacylglycerol (r (s) = 0.09); and uric acid (r (s) = -0.08; all p a parts per thousand currency signaEuro parts per thousand 0.001). Significantly higher albumin excretion rates were found for the following categorical variables: higher waist circumference (more marked in men); presence of the metabolic syndrome; smoking (difference more marked in males); female sex; antihypertensive treatment; use of amlodipine; insulin treatment; family history of diabetes; and family history of cardiovascular disease (more marked in women). Although observational correlations do not prove causality, in normoalbuminuric type 2 diabetic patients the albumin excretion rate is correlated with many factors that are potentially susceptible to intervention. ClinicalTrials.gov ID no.: NCT00185159 This study was sponsored by Daichii-Sankyo.
引用
收藏
页码:49 / 57
页数:9
相关论文
共 50 条
  • [1] Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
    E. Ritz
    G. C. Viberti
    L. M. Ruilope
    A. J. Rabelink
    J. L. Izzo
    S. Katayama
    S. Ito
    A. Mimran
    J. Menne
    L. C. Rump
    A. Januszewicz
    H. Haller
    Diabetologia, 2010, 53 : 49 - 57
  • [2] Erratum to: Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
    E. Ritz
    G. C. Viberti
    L. M. Ruilope
    A. J. Rabelink
    J. L. Izzo
    S. Katayama
    S. Ito
    A. Mimran
    J. Menne
    L. C. Rump
    A. Januszewicz
    H. Haller
    Diabetologia, 2010, 53 (2) : 397 - 397
  • [3] Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes from the RIACE cohort
    Penno, G.
    Solini, A.
    Giacomo, Z.
    Orsi, E.
    Fondelli, C.
    Zerbini, G.
    Trevisan, R.
    Vedovato, M.
    Cavalot, F.
    Gruden, G.
    Lamacchia, O.
    Pugliese, G.
    DIABETOLOGIA, 2014, 57 : S43 - S43
  • [4] DETERMINANTS OF ALBUMIN EXCRETION IN NORMOALBUMINURIC PATIENTS WITH TYPE 2 DIABETES (ROADMAP STUDY)
    Ritz, E.
    Viberti, G.
    Mimran, A.
    Rabelink, A.
    Januszewicz, A.
    Rump, L.
    Ruilope, L.
    Katayama, S.
    Ito, S.
    Izzo, J.
    Haller, H.
    JOURNAL OF HYPERTENSION, 2009, 27 : S336 - S336
  • [6] Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP)
    Ritz, Eberhard
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2011, 121 (05): : 145 - 147
  • [7] Preventing microalbuminuria in patients with diabetes: rationale and design of the Randornised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
    Haller, H
    Viberti, GC
    Mimran, A
    Remuzzi, G
    Rabelink, AJ
    Ritz, E
    Rump, LC
    Ruilope, LM
    Katayama, S
    Ito, S
    Izzo, JL
    Januszewicz, A
    JOURNAL OF HYPERTENSION, 2006, 24 (02) : 403 - 408
  • [8] Ezetimibe Reduces Urinary Albumin Excretion in Hypercholesterolaemic Type 2 Diabetes Patients with Microalbuminuria
    Nakamura, T.
    Sato, E.
    Amaha, M.
    Kawagoe, Y.
    Maeda, S.
    Inoue, H.
    Yamagishi, S. I.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (02) : 798 - 803
  • [9] Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
    Haller, Hermann
    Ito, Sadayoshi
    Izzo, Joseph L., Jr.
    Januszewicz, Andrzej
    Katayama, Shigehiro
    Menne, Jan
    Mimran, Albert
    Rabelink, Ton J.
    Ritz, Eberhard
    Ruilope, Luis M.
    Rump, Lars C.
    Viberti, Giancarlo
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (10): : 907 - 917
  • [10] Prevention of microalbuminuria in type 2 diabetes (ROADMAP Trial)
    Haller, H.
    Januszewicz, A.
    Mimran, A.
    Menne, J.
    Rabelink, T.
    Ritz, E.
    Rump, L. C.
    Ruilope, L. M.
    Viberti, G. C.
    EUROPEAN HEART JOURNAL, 2010, 31 : 321 - 321